COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study
Menée à partir de données portant sur 119 patients atteints d'un cancer et 214 témoins (durée médiane de suivi : 32,7 mois), cette étude de cohorte rétrospective évalue l'association entre une infection par la COVID-19 et le risque de thrombose
COVID-19 has been associated with an increased thrombotic risk, potentially exacerbated in patients with active cancer. We conducted a retrospective cohort study including 119 cancer patients with COVID-19 and 214 matched pre-pandemic controls. Patients with COVID-19 had poorer performance status and were more frequently treated with palliative intent. After a median follow-up of 32.7 months, overall thrombotic event rates did not differ between groups. However, after adjustment for clinically relevant covariates and accounting for death as a competing event, COVID-19 status and palliative treatment intent remained independently associated with a higher cumulative incidence of thrombotic events. In conclusion, COVID-19 may increase thrombotic risk in patients with cancer and occurs more frequently in patients with poorer clinical status. These findings are exploratory and require confirmation in larger prospective studies.
JNCI Cancer Spectrum , résumé, 2026